GENPHARMA (GENPHARMA) Fair Value & Analysis
Other · IN · Market cap ₹615M
Fair value as of: Jul 5, 2026
From 11 valuation models · updated today
Share price −3.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹0.7800 – ₹2.07 · fair‑value band ₹0.4900 – ₹0.6300 · the ₹1.11 price screens above the ₹0.4900 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
GENPHARMA (GENPHARMA) currently trades at ₹1.11, while our model-based Fair Value estimate is ₹0.4900 — implying the stock looks roughly 55.9% overvalued today. We read business quality at 37/100 (below-average quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, GENPHARMA generated revenue of ₹1.4B at a net margin of 1.2%. Revenue grew 295.6% year over year. It earns a return on equity of 0.9%. Net debt stands at ₹320M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹0.4900 (bear case) to ₹0.6300 (bull case); at ₹1.11, the current price sits above that range. The share trades about 50% below its 52-week high and 48% above its 52-week low, currently below its 200-day average. For context, the median of 10 Other peers we cover trades at -16% fair-value upside — at -56%, GENPHARMA screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
GENPHARMA reported revenue of ₹1.4B in FY2026 versus ₹266M in FY2022, a compound +51.4%/yr. Reported net income was ₹16.0M in FY2026.
Is GENPHARMA fairly valued? → Check now
Similar stocks
10 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €209.16 | -60% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $28.75 | +71% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
| 540777 540777 | ₹567.55 | ₹142.69 | -75% |
| Lupin Limited 500257 | ₹2,476 | ₹2,372 | -4% |
| 540719 540719 | ₹1,788 | ₹850.02 | -52% |
| 524804 524804 | ₹1,620 | ₹1,368 | -16% |
Explore undervalued stocks
Frequently asked questions
Is GENPHARMA (GENPHARMA) undervalued?
What is the fair value of GENPHARMA?
What is the quality score of GENPHARMA?
What is the revenue of GENPHARMA (GENPHARMA)?
What is the net profit margin of GENPHARMA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.